Vertex reports strong Week 36 IgA nephropathy results from RAINIER trial
Vertex says its RAINIER study showed clear kidney improvements with povetacicept, while interim AMPLITUDE data are expected in early 2027.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Vertex said that in the RAINIER study, povetacicept produced notable gains at Week 36 in patients with IgA nephropathy, with lower proteinuria, reduced Gd-IgA1 and less hematuria. The drug's tolerability was described as generally favorable. The information was published by TradingView, and the text is an AI-generated summary that may contain inaccuracies.
The AMPLITUDE study has enrolled 522 patients, and its interim data are targeted for early 2027. The company also plans to bring four potential kidney treatments to market by 2030.
why it matters
Kidney disease is a key growth area for Vertex, so updates on its drug pipeline draw investor attention. The next major milestone will be the AMPLITUDE interim data, which will show whether the RAINIER results hold in a larger patient group.
market impact
Vertex shares: strong drug data supports expectations for growth in kidney disease treatments
tags
instruments
sources
- VRTX: RAINIER showed strong Week 36 IgAN results; AMPLITUDE interim data are targeted for early 2027 — TradingView, 24 October 2026 at 00:17 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗